Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T14:51:28.111Z.
Calculation as of: 2026-10-06T14:51:28.111Z.
Quote observation: 2026-10-06T14:50:27.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6abed0f02887b3ac62520bc322e243c8ff06f4fcddd7c97914d2a236e2670171
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
ClearPoint Neuro, Inc.
Market Cap
$331.54M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$332.31M
Operating Cash Flow Yield
N/A
TTM Avg
1.16%
3Y Avg
1.16%
5Y Avg
1.16%
Market Cap
$322.98M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$320.81M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$320.09M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$345.16M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$350.32M
Operating Cash Flow Yield
N/A
TTM Avg
3.39%
3Y Avg
3.76%
5Y Avg
5.04%
Market Cap
$350.35M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$353.89M
Operating Cash Flow Yield
49.20%
TTM Avg
54.62%
3Y Avg
24.22%
5Y Avg
23.43%
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ClearPoint Neuro, Inc. (CLPT) | $331.54M | N/A | N/A | N/A | N/A |
| Agenus Inc. (AGEN)vs › | $332.31M | N/A | 1.16% | 1.16% | 1.16% |
| CapsoVision, Inc. (CV)vs › | $322.98M | N/A | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $320.81M | N/A | N/A | N/A | N/A |
| C4 Therapeutics, Inc. (CCCC)vs › | $320.09M | N/A | N/A | N/A | N/A |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $345.16M | N/A | N/A | N/A | N/A |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $350.32M | N/A | 3.39% | 3.76% | 5.04% |
| Opus Genetics, Inc. (IRD)vs › | $350.35M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $353.89M | 49.20% | 54.62% | 24.22% | 23.43% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $354.67M | N/A | 15.24% | 15.24% | 15.24% |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
